Cyclic and linear peptides containing the Asn-Gly-Arg (NGR) motif have proven useful for delivering various anti-tumor compounds and viral particles to tumor vessels. We have investigated the role of cyclic constraints on the structure and tumor-homing properties of NGR peptides using tumor necrosis factor-␣ (TNF) derivatives containing disulfide-bridged (CNGRC-TNF) and linear (GNGRG-TNF) NGR domains. Experiments carried out in animal models showed that both GNGRG and CNGRC can target TNF to tumors. However, the antitumor activity of CNGRC-TNF was >10-fold higher than that of GNGRG-TNF. Molecular dynamic simulation of cyclic CNGRC showed the presence of a bend geometry involving residues Gly 3 -Arg 4 . Molecular dynamic simulation of the same peptide without disulfide constraints showed that the most populated and thermodynamically favored configuration is characterized by the presence of a -turn involving residues Gly 3 -Arg 4 and hydrogen bonding interactions between the backbone atoms of Asn 2 and Cys 5 . These results suggest that the NGR motif has a strong propensity to form -turn in linear peptides and may explain the finding that GNGRG peptide can target TNF to tumors, albeit to a lower extent than CNGRC. The disulfide bridge constraint is critical for stabilizing the bent conformation and for increasing the tumor targeting efficiency.Phage display peptide libraries are commonly used to obtain peptide sequences interacting with proteins differentially expressed in normal and pathological tissues (1, 2). For instance, in vivo panning of phage libraries in tumor-bearing animals have proven useful for selecting peptides able to interact with proteins expressed within tumor-associated vessels and to home to neoplastic tissues (3). Among the various tumor targeting ligands identified so far, the CNGRC peptide have proven useful for delivering various anti-tumor compounds, like chemotherapeutic drugs, apoptotic peptides and cytokines, to tumor vessels (3-5). For example, we have recently shown that targeted delivery of tumor necrosis factor-␣ (TNF) 1 to tumor vasculature can be obtained by coupling its N terminus to the C terminus of the CNGRC peptide, by genetic engineering technology (5). This approach markedly improved the therapeutic index of TNF in animal models, either when used alone (5) or in combination with chemotherapeutic agents (6). Studies on the mechanism of action showed that the targeting domain of this TNF derivative (called NGR-TNF) binds an aminopeptidase (CD13) isoform expressed in tumor vessels, and not other isoforms expressed in normal epithelia or myeloid cells (7). Besides CNGRC, other tumor vasculature targeting peptides containing the NGR motif have been identified, such as linear NGRAHA and cyclic CVLNGRMEC (3). These and other linear and cyclic NGR peptides have been used for targeting viral particles to endothelial cells (8, 9). Although these findings may suggest that peptide cyclization is not necessary for the targeting properties of NGR peptides, the role of cysteines and th...